written by reader Cytodyn (CYDY)

By OSUfball, May 7, 2020

Cytodyn (CYDY) is a stock that was discussed in depth here around 4 years ago. The company makes a monoclonal antibody called leronlimab (formerly known as PRO 140) which is a CCR5 inhibitor for treating HIV. The BLA has been submitted for it and the FDA has granted it fast track designation and a decision should be coming in the next 6 months. Recently CYDY discovered that by blocking CCR5 leronlimab can also block a cytokine called RANTES that needs to use CCR5 to enter the cell. This cytokine is believed to be the principal one causing the inflammation in the lungs in Covid19. So CYDY is also pushing for leronlimab as a treatment for Covid19. CYDY seems like it might be a good speculative investment for those with high risk tolerance. I’ve put together some current resources on it:

The company will soon be publishing a paper in what is rumored to be the journal Nature with its findings, and a pre-print has been released here:

New Production Order with Aji Bio Pharma:
FDA Approving 54 Emergency INDs for Leronlimab:
CEO Nader exercising warrants for help finance the company:
Dr. Yo & Dr. Hansen unbiased discussions about how incredible Leronlimab is:
Dr. Yang at UCLA comapring the various treatments for COVID19 and Leronlimab:

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.